Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Sep 10, 2026
Reporting period
Not applicable
Filed with the SEC
Sep 15, 2026
OfficerGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001193125-26-390624
Filed / recorded
Sep 15, 2026, 12:24 AM UTC
Added to OQRO
Oct 8, 2026, 12:20 AM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
BridgeBio Oncology Therapeutics, Inc.
Issuer CIK
1869105
Ticker
BBOT
Reporting person
Marc Cobo
Relationship
Officer
Officer title
Principal Accounting Officer
Security
Common Stock
Table
Non-derivative (Table I)
Transaction date
Sep 10, 2026
Transaction code
A
Shares / units
9,038
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
14,344
Ownership form
Direct
Amendment
No
Footnotes from the filing
Represents a grant of restricted stock units ("RSUs"), each representing a contingent right to receive one share of the Issuer's Common Stock. The RSUs vest in 16 equal quarterly installments over a period of four years from April 21, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. The RSUs will be settled in shares of Common Stock upon vesting.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.